December 10, 2016Scripta Scientifica MedicaOpen Access

B-type natriuretic peptide levels - A new biomarker in the acute coronary syndrome

View Full Paper

Ask AI

Bookmark

Why the study?

Do elevated BNP and NT-proBNP levels predict adverse cardiovascular outcomes and enhance risk stratification in patients with acute coronary syndromes?

Population

Patients with acute coronary syndromes (ACS), including STEMI and non-STEMI

Design

Review

Authors

KVKaterina VitlianovaMedical University of Varna

Discussion

Member takes

Implication

May extend BNP role in ACS ischemia assessment; leaves open prospective validation before practice change.

Structured PICO

Do elevated BNP and NT-proBNP levels predict adverse cardiovascular outcomes and enhance risk stratification in patients with acute coronary syndromes?

Population

Patients with acute coronary syndromes (ACS), including STEMI and non-STEMI

Intervention

Measurement of B-type natriuretic peptide (BNP) and N-terminal B-type natriuretic peptide (NT-proBNP) levels

Outcome

Risk stratification, cardiovascular events, and cardiac mortality

BNP and NT-proBNP are valuable prognostic biomarkers that enhance risk stratification for cardiovascular events and mortality in patients with acute coronary syndromes.

Cite This Study

Katerina Vitlianova (2016) studied this question.

synapsesocial.com/papers/6a6ff1f235aa2c282ce14061 https://doi.org/10.14748/ssm.v48i4.1943

View Full Paper

Ask AI

Bookmark

B-type natriuretic peptide levels - A new biomarker in the acute coronary syndrome

Discussion

Member takes

Implication

Structured PICO

Cite This Study

B-type natriuretic peptide levels - A new biomarker in the acute coronary syndrome

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider